Literature DB >> 8369512

Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme.

M Datta1, M P Radhamani, R Selvaraj, C N Paramasivan, B N Gopalan, C R Sudeendra, R Prabhakar.   

Abstract

This is a status report of a retrospectively assembled cohort of 3357 smear-positive patients initiated on anti-tuberculosis chemotherapy in the North Arcot district between April 1986 and March 1988. The patients were contacted once at their homes between November 1988 and June 1989 (6 and 36 months after start of treatment), and information on their status, including death, could be obtained from 76% of them. Regimens were selected by the patients. 2306 (69%) had accepted short course regimens (SCC) and 1051 (31%) had been started on standard chemotherapy (non-SCC), 43% and 35% in SCC and non-SCC respectively had completed 80% or more of their treatment. Overall mortality was 28%. Of those remaining, 31% had active disease and were excreting bacilli, among which 65% of the cultures were resistant to isoniazid and 12% to rifampicin. Combined resistance to isoniazid and rifampicin was seen in 4% and to isoniazid and streptomycin was seen in 19%. A significant finding was that even among those who had taken less than 50% of their treatment, 56% were bacteriologically negative. However, inadequate or irregular chemotherapy resulted in over four times the mortality and about twice the rate of smear positivity as compared with those taking adequate chemotherapy. No comparisons are made between patients on short-course and standard regimens as the patients selected their treatment and the groups are not comparable.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8369512     DOI: 10.1016/0962-8479(93)90008-L

Source DB:  PubMed          Journal:  Tuber Lung Dis        ISSN: 0962-8479


  11 in total

Review 1.  Multidrug-resistant to extensively drug resistant tuberculosis: what is next?

Authors:  Amita Jain; Pratima Dixit
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

2.  PREVALENCE OF DRUG RESISTANT TUBERCULOSIS IN ARMED FORCES-STUDY FROM A TERTIARY REFERRAL CHEST DISEASES HOSPITAL AT PUNE.

Authors:  Kailash Chand; S C Tewari; S J Varghese
Journal:  Med J Armed Forces India       Date:  2017-06-10

3.  A chain-binomial model for intra-household spread of Mycobacterium tuberculosis in a low socio-economic setting in Pakistan.

Authors:  S Akhtar; T E Carpenter; S K Rathi
Journal:  Epidemiol Infect       Date:  2006-06-02       Impact factor: 2.451

4.  Evaluation of a directly observed six months fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance.

Authors:  J A Caminero; J M Pavón; F Rodríguez de Castro; F Díaz; G Julià; J A Caylá; P Cabrera
Journal:  Thorax       Date:  1996-11       Impact factor: 9.139

5.  Five-year trend of acquired antitubercular drug resistance in patients attending a tertiary care hospital at Dehradun (Uttarakhand).

Authors:  Jagdish Rawat; G Sindhwani; Ruchi Juyal; Ruchi Dua
Journal:  Lung India       Date:  2009-10

Review 6.  Current and potential treatment of tuberculosis.

Authors:  S Houston; A Fanning
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

Review 7.  Tuberculosis in the AIDS era.

Authors:  K A Sepkowitz; J Raffalli; L Riley; T E Kiehn; D Armstrong
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

8.  Mortality and associated risk factors in a cohort of tuberculosis patients treated under DOTS programme in Addis Ababa, Ethiopia.

Authors:  Belete Getahun; Gobena Ameni; Sibhatu Biadgilign; Girmay Medhin
Journal:  BMC Infect Dis       Date:  2011-05-16       Impact factor: 3.090

9.  Counting the lives saved by DOTS in India: a model-based approach.

Authors:  Sandip Mandal; Vineet K Chadha; Ramanan Laxminarayan; Nimalan Arinaminpathy
Journal:  BMC Med       Date:  2017-03-03       Impact factor: 8.775

10.  Tuberculosis-related deaths within a well-functioning DOTS control program.

Authors:  Maria De Lourdes García-García; Alfredo Ponce-De-León; Maria Cecilia García-Sancho; Leticia Ferreyra-Reyes; Manuel Palacios-Martínez; Javier Fuentes; Midori Kato-Maeda; Miriam Bobadilla; Peter Small; José Sifuentes-Osornio
Journal:  Emerg Infect Dis       Date:  2002-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.